- Home
- EBS vs RIGL Comparison
EBS vs RIGL Comparison
Compare EBS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | RIGL |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.6M | 628.4M |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EBS | RIGL |
|---|---|---|
| Price | $8.39 | $28.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 1.0M | 332.3K |
| Earning Date | 05-27-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 125.83 | ★ 1867.68 |
| EPS | 0.93 | ★ 19.48 |
| Revenue | ★ $742,900,000.00 | $294,282,000.00 |
| Revenue This Year | $29.50 | $66.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.89 | ★ $1.48 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $4.02 | $15.50 |
| 52 Week High | $14.06 | $52.24 |
Technical Indicators
Market Signals| Indicator | EBS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 30.16 | 26.00 |
| Support Level | $7.66 | $27.23 |
| Resistance Level | $9.68 | $31.26 |
| Average True Range (ATR) | 0.58 | 1.71 |
| MACD | -0.21 | -0.56 |
| Stochastic Oscillator | 15.48 | 6.52 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.